Market Place
Sourcing Support
Cellectar & NorthStar Partner for Actinium-225 Supply
14 Nov 2024 //
GLOBENEWSWIRE
Cellectar Bio to Report Q3 Financial Results & Host Call on Nov 18
11 Nov 2024 //
GLOBENEWSWIRE
Cellectar Announces Tranche A Warrants Exercised, Providing Proceeds of $44.1M
25 Jan 2024 //
PRESS RELEASE
Cellectar Reports CNS Clearance in Waldenstrom’s Macroglobulinemia Patient
22 Jan 2024 //
PRESS RELEASE
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT)
16 Jan 2024 //
PRESS RELEASE
Cellectar to Host Conference Call with Texas Oncology Hematologist M. Yair Levy
12 Jan 2024 //
PRESS RELEASE
Cellectar Biosciences Partners with MiBA
11 Jan 2024 //
PRESS RELEASE
Cellectar Biosciences Announces Positive Topline Data in Study of Iopofosine
08 Jan 2024 //
PRESS RELEASE
Cellectar to Announce Top-line Data from WM Pivotal Trial on January 8, 2024
03 Jan 2024 //
PRESS RELEASE
Cellectar Announces Publication of Data from Its PhII CLOVER-1 Iopofosine I-131
13 Sep 2022 //
GLOBENEWSWIRE
Cellectar Announces Stock Consolidation
21 Jul 2022 //
CELLECTAR
Cellectar, Evergreen Enter Clinical Manufacturing and Supply Agreement
17 Aug 2021 //
CONTRACT PHARMA
Cellectar Receives Orphan Drug Designation from the European for CLR 131
28 Jan 2021 //
GLOBENEWSWIRE
Cellectar`s lead asset shows 40% response rate in multiple myeloma study
08 Sep 2020 //
SEEKINGALPHA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.